We Venture Capital & ClavystBio Lead in HealthTech Firm, Respiree
25 Jul 2025
US$ 20.00
US-based We Venture Capital (We VC) and Singapore’s ClavystBio have co-led the US$11.6 m series A funding round of R...
Related Publications
Subscribers’ Weekly...
Listen to Australia/New Zealand Funds (Subscribers' Weekly 01 Aug 2025)...
Connect With Us
We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.
Rest assured that your email address will not be shared, as we hate spams as much as you do.